Relapsing-remitting Multiple Sclerosis (RRMS)
Conditions
Brief summary
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
Detailed description
This was a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatimer acetate 20 mg s.c. in patients with RRMS. This study consisted of 3 periods: * Screening Period: up to 45 days for all patients * Treatment Period: 12 months of glatiramer acetate 20 mg, fingolimod 0.25 mg, or fingolimod 0.5 mg * Follow-up occurred 3 months (12 weeks) after the last dose of study drug for all patients The informed consent form was signed prior to any study related activities at the screening visit. Randomization to either treatment group was preformed at visit 1 after a diligent check of applicable in- and exclusion criteria in a 1:1:1 ratio (changed to 5:3:2 after implementation of Amendment 2 in 2015). Treatment groups: * fingolimod 0.5 mg/day orally for up to 12 months * fingolimod 0.25 mg/day orally for up to 12 months * glatiramer acetate 20 mg/day subcutaneously for up to 12 months
Interventions
DRUGfingolimod
capsule
DRUGglatiramer acetate
subcutaneous injection
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Fingolimod patients were dose blind.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent must be obtained before any assessment is performed * Male and female patients 18 to 65 years of age, inclusive. * Patients with RRMS, as defined by 2010 revised McDonald criteria. * Patients must be neurologically stable with no onset of relapse within 30 days of randomization * Patients with at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years before randomization. * Patients with an EDSS score of 0 to 6, inclusive, at Screening. A score of 6.0 indicates unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting.
Exclusion criteria
* Patients with a history of malignancy of any organ system (other than cutaneous basal cell carcinoma) in the last 5 years that do not have confirmation of absence of a malignancy prior to randomization * Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjogren's syndrome, Crohn's disease, ulcerative colitis) or with a known immunodeficiency syndrome (HIV-antibody positive, AIDS, hereditary immune deficiency, drug-induced immune deficiency). * Patients who have been treated with: * High-dose intravenous (IV) immunoglobulin (Ig) within 4 weeks before randomization * Immunosuppressive/chemotherapeutic medications (e.g., azathioprine, cyclophosphamide, methotrexate) within 6 months before randomization * Natalizumab within 2 months before randomization * Previous treatment with lymphocyte-depleting therapies (e.g., rituximab, alemtuzumab, ofatumumab, ocrelizumab, or cladribine) within 1 year before randomization Previous treatment with mitoxantrone within 6 months before randomization * Use of teriflunomide within 3.5 months prior to randomization, except if active washout (with either cholestyramine or activated charcoal) was done. In that case, plasma levels are required to be measured and be below 0.02 mg/L before randomization. No washout period is necessary for patients treated with dimethyl fumarate, interferon (IFN) beta, or glatiramer acetate. Patients being treated with dimethyl fumarate, glatiramer acetate, or IFN beta at the Screening visit can continue drug intake up to the day before Day 1 of this study (i.e., there is no need for a washout period). * Patients who have been treated with systemic corticosteroids or adrenocorticotropic hormones in the past 30 days prior to the screening magnetic resonance imaging (MRI) procedure. * Patients with uncontrolled diabetes mellitus (glycosylated hemoglobin \>9%) or with diabetic neuropathy. * Patients with a diagnosis of macular edema during Screening (patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at Screening). * Patients with severe active bacterial, viral, or fungal infections. * Patients without acceptable evidence of immunity to varicella zoster virus (VZV) at randomization. * Patients who have received any live or live-attenuated vaccines (including VZV, herpes simplex, or measles) within 1 month before randomization. * Patients who have received total lymphoid irradiation or bone marrow transplantation. * Patients with any unstable medical/psychiatric condition, as assessed by the primary treating physician at each site. * Patients who in the last 6 months experienced any of the following cardiovascular conditions or findings in the screening electrocardiogram (ECG): myocardial infarction, unstable angina, stroke, transient ischemic attack or decompensated heart failure requiring hospitalization or Class III/IV heart failure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Annualized Relapse Rate | up to 12 months | Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Free of New/Newly Enlarged T2 Lesions | At 12 months/end of study | Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count. |
| Change From Baseline in T2 Lesion Volume | Baseline, 12 months/end of study | Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume |
| Gd Enhancing T1 Lesion Count | At 12 months/end of study | Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count |
| New or Newly Enlarging T2 Lesions | At 12 months/end of study | Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count. |
| Percentage of Patients Free of New T1 Hypointense Lesions | 12 months | Based on MRI measures of new T1 hypointense lesions |
| Change From Baseline in TSQM Scales | 6 months, 12 months/end of study | Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug. |
| Percent Brain Volume Change From Baseline | Baseline, 12 months, end of study | Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation. |
| Gd Enhancing T1 Lesion Volume | Baseline, 12 months/end of study | Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count |
Countries
Argentina, Brazil, Canada, Chile, Mexico, Puerto Rico, United States
Participant flow
Pre-assignment details
A total of 1461 subjects were screened for participation in this study; of those, 1064 subjects were randomly assigned to study treatment
Participants by arm
| Arm | Count |
|---|---|
| FTY720 0.5 mg Fingolimod (FTY720) 0.5 mg orally once a day for up to 12 months | 352 |
| FTY720 0.25 mg Fingolimod (FTY720) 0.25 mg orally once a day for up to 12 months | 370 |
| GA 20 mg Glatiramer acetate (GA) 20 mg s.c. once a day for up to 12 months | 342 |
| Total | 1,064 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Abnormal laboratory value(s) | 3 | 1 | 0 |
| Overall Study | Abnormal test procedure result(s) | 0 | 1 | 0 |
| Overall Study | Administrative problems | 1 | 2 | 5 |
| Overall Study | Adverse Event | 16 | 18 | 20 |
| Overall Study | Lack of Efficacy | 1 | 6 | 13 |
| Overall Study | Lost to Follow-up | 7 | 19 | 6 |
| Overall Study | missing Study Completion CRF | 1 | 1 | 4 |
| Overall Study | Protocol Violation | 4 | 0 | 2 |
| Overall Study | Subject no longer requires study drug | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 20 | 12 | 41 |
Baseline characteristics
| Characteristic | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg | Total |
|---|---|---|---|---|
| Age, Continuous | 40.3 Years STANDARD_DEVIATION 11.12 | 38.9 Years STANDARD_DEVIATION 11.01 | 39.6 Years STANDARD_DEVIATION 10.8 | 39.6 Years STANDARD_DEVIATION 10.98 |
| Race/Ethnicity, Customized Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black | 34 Participants | 43 Participants | 41 Participants | 118 Participants |
| Race/Ethnicity, Customized Caucasian | 268 Participants | 279 Participants | 243 Participants | 790 Participants |
| Race/Ethnicity, Customized Native American | 8 Participants | 7 Participants | 9 Participants | 24 Participants |
| Race/Ethnicity, Customized Other | 42 Participants | 39 Participants | 49 Participants | 130 Participants |
| Race/Ethnicity, Customized Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Female | 264 Participants | 276 Participants | 252 Participants | 792 Participants |
| Sex: Female, Male Male | 88 Participants | 94 Participants | 90 Participants | 272 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 345 | 0 / 366 | 0 / 324 | 0 / 1,035 |
| other Total, other adverse events | 214 / 345 | 245 / 366 | 190 / 324 | 649 / 1,035 |
| serious Total, serious adverse events | 25 / 345 | 32 / 366 | 20 / 324 | 77 / 1,035 |
Outcome results
Primary
Confirmed Annualized Relapse Rate
Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study.
Time frame: up to 12 months
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FTY720 0.5 mg | Confirmed Annualized Relapse Rate | 0.153 relapses/year |
| FTY720 0.25 mg | Confirmed Annualized Relapse Rate | 0.221 relapses/year |
| GA 20 mg | Confirmed Annualized Relapse Rate | 0.258 relapses/year |
Comparison: H01: µ FTY 0.5 mg = µ GA versus HA1: µ FTY 0.5 mg ≠µ GA H02: µ FTY 0.25 mg = µ GA versus HA2: µ FTY 0.25 mg ≠µ GAp-value: 0.0138negative binomial regression model
Comparison: H01: µ FTY 0.5 mg = µ GA versus HA1: µ FTY 0.5 mg ≠µ GA H02: µ FTY 0.25 mg = µ GA versus HA2: µ FTY 0.25 mg ≠µ GAp-value: 0.4153negative binomial regression model
Secondary
Change From Baseline in T2 Lesion Volume
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume
Time frame: Baseline, 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FTY720 0.5 mg | Change From Baseline in T2 Lesion Volume | -0.14 cubic centimeters (cc) | Standard Deviation 1.583 |
| FTY720 0.25 mg | Change From Baseline in T2 Lesion Volume | -0.05 cubic centimeters (cc) | Standard Deviation 2.34 |
| GA 20 mg | Change From Baseline in T2 Lesion Volume | 0.42 cubic centimeters (cc) | Standard Deviation 2.305 |
p-value: <0.0001ANCOVA
p-value: 0.006ANCOVA
Secondary
Change From Baseline in TSQM Scales
Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.
Time frame: 6 months, 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 6) | 20.8 score on a scale | Standard Deviation 28.15 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 12) | 19.2 score on a scale | Standard Deviation 31.87 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 6) | 15.2 score on a scale | Standard Deviation 25.96 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 12) | 16.8 score on a scale | Standard Deviation 26.85 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Side Effects (Month 6) | 16.9 score on a scale | Standard Deviation 31.58 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Side Effects (Month 12) | 16.2 score on a scale | Standard Deviation 31.52 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Convenience (Month 6) | 30.7 score on a scale | Standard Deviation 25.76 |
| FTY720 0.5 mg | Change From Baseline in TSQM Scales | Convenience (Month 12) | 29.5 score on a scale | Standard Deviation 24.42 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 6) | 18.2 score on a scale | Standard Deviation 25.05 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Convenience (Month 6) | 26.5 score on a scale | Standard Deviation 25.93 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 12) | 17.9 score on a scale | Standard Deviation 28.29 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Side Effects (Month 6) | 18.8 score on a scale | Standard Deviation 30.63 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Side Effects (Month 12) | 17.2 score on a scale | Standard Deviation 32.52 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 6) | 23.4 score on a scale | Standard Deviation 27.04 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 12) | 20.5 score on a scale | Standard Deviation 32.21 |
| FTY720 0.25 mg | Change From Baseline in TSQM Scales | Convenience (Month 12) | 26.5 score on a scale | Standard Deviation 26.36 |
| GA 20 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 6) | 12.9 score on a scale | Standard Deviation 23.43 |
| GA 20 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 12) | 9.4 score on a scale | Standard Deviation 30.43 |
| GA 20 mg | Change From Baseline in TSQM Scales | Global Satisfaction (Month 6) | 14.4 score on a scale | Standard Deviation 25.42 |
| GA 20 mg | Change From Baseline in TSQM Scales | Effectiveness (Month 12) | 8.0 score on a scale | Standard Deviation 27.38 |
| GA 20 mg | Change From Baseline in TSQM Scales | Convenience (Month 6) | 4.4 score on a scale | Standard Deviation 20.73 |
| GA 20 mg | Change From Baseline in TSQM Scales | Side Effects (Month 12) | 7.6 score on a scale | Standard Deviation 32.76 |
| GA 20 mg | Change From Baseline in TSQM Scales | Side Effects (Month 6) | 9.3 score on a scale | Standard Deviation 31.94 |
| GA 20 mg | Change From Baseline in TSQM Scales | Convenience (Month 12) | 0.8 score on a scale | Standard Deviation 25.72 |
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: 0.0005Wilcoxon signed-rank test
p-value: <0.0051Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: 0.0051Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: 0.0068Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: <0.0001Wilcoxon signed-rank test
p-value: 0.4595Wilcoxon signed-rank test
Secondary
Gd Enhancing T1 Lesion Count
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
Time frame: At 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FTY720 0.5 mg | Gd Enhancing T1 Lesion Count | 0.4 lesions | Standard Deviation 1.57 |
| FTY720 0.25 mg | Gd Enhancing T1 Lesion Count | 0.4 lesions | Standard Deviation 1.56 |
| GA 20 mg | Gd Enhancing T1 Lesion Count | 0.9 lesions | Standard Deviation 3.67 |
p-value: 0.0167negative binomial regression model
p-value: 0.0011negative binomial regression model
Secondary
Gd Enhancing T1 Lesion Volume
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
Time frame: Baseline, 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| FTY720 0.5 mg | Gd Enhancing T1 Lesion Volume | Baseline | 0.31 cubic centimeter | Standard Deviation 1.067 |
| FTY720 0.5 mg | Gd Enhancing T1 Lesion Volume | Month 12/end of study | 0.06 cubic centimeter | Standard Deviation 0.215 |
| FTY720 0.25 mg | Gd Enhancing T1 Lesion Volume | Baseline | 0.32 cubic centimeter | Standard Deviation 1.421 |
| FTY720 0.25 mg | Gd Enhancing T1 Lesion Volume | Month 12/end of study | 0.05 cubic centimeter | Standard Deviation 0.181 |
| GA 20 mg | Gd Enhancing T1 Lesion Volume | Month 12/end of study | 0.12 cubic centimeter | Standard Deviation 0.45 |
| GA 20 mg | Gd Enhancing T1 Lesion Volume | Baseline | 0.22 cubic centimeter | Standard Deviation 0.841 |
p-value: 0.0052ANCOVA
p-value: 0.0636ANCOVA
Secondary
New or Newly Enlarging T2 Lesions
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
Time frame: At 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FTY720 0.5 mg | New or Newly Enlarging T2 Lesions | 2.6 Lesions | Standard Deviation 5.42 |
| FTY720 0.25 mg | New or Newly Enlarging T2 Lesions | 3.3 Lesions | Standard Deviation 6.94 |
| GA 20 mg | New or Newly Enlarging T2 Lesions | 5.7 Lesions | Standard Deviation 10.71 |
p-value: <0.0001negative binomial regression model
p-value: <0.0001negative binomial regression model
Secondary
Number of Participants Free of New/Newly Enlarged T2 Lesions
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
Time frame: At 12 months/end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FTY720 0.5 mg | Number of Participants Free of New/Newly Enlarged T2 Lesions | 156 Participants |
| FTY720 0.25 mg | Number of Participants Free of New/Newly Enlarged T2 Lesions | 155 Participants |
| GA 20 mg | Number of Participants Free of New/Newly Enlarged T2 Lesions | 96 Participants |
Secondary
Percentage of Patients Free of New T1 Hypointense Lesions
Based on MRI measures of new T1 hypointense lesions
Time frame: 12 months
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FTY720 0.5 mg | Percentage of Patients Free of New T1 Hypointense Lesions | 55.3 Percentage |
| FTY720 0.25 mg | Percentage of Patients Free of New T1 Hypointense Lesions | 52.1 Percentage |
| GA 20 mg | Percentage of Patients Free of New T1 Hypointense Lesions | 44.3 Percentage |
p-value: 0.0011Regression, Logistic
p-value: 0.0146Regression, Logistic
Secondary
Percent Brain Volume Change From Baseline
Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation.
Time frame: Baseline, 12 months, end of study
Population: Full-analysis set: All subjects who were randomly assigned and took at least 1 dose of study drug. Following the intent-to-treat principle, subjects were grouped according to the assigned treatment at randomization. Efficacy analyses were performed using the full analysis set unless otherwise notified.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FTY720 0.5 mg | Percent Brain Volume Change From Baseline | -0.652 Percentages of volume change | Standard Deviation 0.781 |
| FTY720 0.25 mg | Percent Brain Volume Change From Baseline | -0.636 Percentages of volume change | Standard Deviation 0.8097 |
| GA 20 mg | Percent Brain Volume Change From Baseline | -0.561 Percentages of volume change | Standard Deviation 0.7819 |
p-value: 0.1045ANCOVA
p-value: 0.1358ANCOVA